Week in Review: China's Luxin Invests in $215 Million Funding for Intarcia's Long-Term Diabetes Device

Luxin Venture Capital of China participated in a $215 million funding of  Boston's Intarcia Therapeutics, a company developing a once-yearly type 2 diabetes treatment; Aspen Pharmacare of South Africa paid GlaxoSmithKline $60 million for rights to two thrombosis drugs in China, India and Pakistan; Tianjin Pharma will invest $20 million in Neuralstem, a Maryland biopharma using stem cells to treat CNS disorders; iCarbonX, China's artificial intelligence, big-data healthcare company, acquired Imagu Vision Technologies of Israel; LIH, a Beijing company specializing in rehabilitation hospitals and clinics, received an investment from Qiming Venture Partners; SciClone Pharma of the US paid $3 million for China rights to a novel oral mucositis treatment from Soligenix; Zhejiang Hisun Pharma engaged GeneriCo, a specialty generic drug company, to be its US sales and marketing partner; Suzhou's Innovent Biologics started a China Phase III trial of its Humira biosimilar and was approved to begin trials of its PD-1 candidate; BeiGene of Beijing received approval to begin China trials of its PD-1 drug to treat advanced solid tumors; and China's Vcanbio Cell & Gene Engineering, a Tianjin stem cell and cord banking company, opened two companies in Boston to invest in cell therapy products. More details.... Stock Symbols: (SHA: 600783) (NYSE: GSK) (NSDQ: CUR) (NSDQ: SCLN) (OTC: SNGX) (SHA: 600267) (NSDQ: BGNE) (SHA: 600645) Share this with colleagues: // //